Citadel Advisors’s Genomic Health, Inc. GHDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q3 | – | Sell |
-291,969
| Closed | -$20.1M | – | 10119 |
|
|
2019
Q2 | $17M | Sell |
291,969
-63,704
| -18% | -$3.77M | 0.01% | 1587 |
|
|
2019
Q1 | $24.9M | Buy |
355,673
+152,241
| +75% | +$11.3M | 0.01% | 1152 |
|
|
2018
Q4 | $13.1M | Buy |
203,432
+32,428
| +19% | +$2.27M | 0.01% | 1610 |
|
|
2018
Q3 | $12M | Buy |
171,004
+35,605
| +26% | +$2.08M | 0.01% | 1904 |
|
|
2018
Q2 | $6.82M | Buy |
135,399
+10,170
| +8% | +$404K | ﹤0.01% | 2377 |
|
|
2018
Q1 | $3.92M | Buy |
125,229
+26,296
| +27% | +$872K | ﹤0.01% | 2757 |
|
|
2017
Q4 | $3.38M | Buy |
98,933
+5,130
| +5% | +$164K | ﹤0.01% | 2951 |
|
|
2017
Q3 | $3.01M | Buy |
93,803
+68,418
| +270% | +$2.16M | ﹤0.01% | 2918 |
|
|
2017
Q2 | $826K | Sell |
25,385
-18,057
| -42% | -$572K | ﹤0.01% | 4372 |
|
|
2017
Q1 | $1.37M | Buy |
+43,442
| New | +$1.29M | ﹤0.01% | 3550 |
|
|
2016
Q4 | – | Sell |
-28,988
| Closed | -$838K | – | 8151 |
|
|
2016
Q3 | $838K | Buy |
28,988
+19,556
| +207% | +$545K | ﹤0.01% | 4061 |
|
|
2016
Q2 | $244K | Sell |
9,432
-31,622
| -77% | -$840K | ﹤0.01% | 5528 |
|
|
2016
Q1 | $1.02M | Buy |
41,054
+14,986
| +57% | +$411K | ﹤0.01% | 3471 |
|
|
2015
Q4 | $918K | Buy |
26,068
+12,059
| +86% | +$323K | ﹤0.01% | 3687 |
|
|
2015
Q3 | $296K | Sell |
14,009
-24,735
| -64% | -$637K | ﹤0.01% | 5578 |
|
|
2015
Q2 | $1.08M | Sell |
38,744
-45,692
| -54% | -$1.29M | ﹤0.01% | 3869 |
|
|
2015
Q1 | $2.58M | Buy |
84,436
+38,467
| +84% | +$1.22M | ﹤0.01% | 2749 |
|
|
2014
Q4 | $1.47M | Buy |
45,969
+8,226
| +22% | +$268K | ﹤0.01% | 3281 |
|
|
2014
Q3 | $1.07M | Sell |
37,743
-152,802
| -80% | -$4.26M | ﹤0.01% | 3629 |
|
|
2014
Q2 | $5.22M | Sell |
190,545
-15,861
| -8% | -$422K | 0.01% | 1802 |
|
|
2014
Q1 | $5.44M | Buy |
206,406
+45,478
| +28% | +$1.3M | 0.01% | 1710 |
|
|
2013
Q4 | $4.71M | Buy |
160,928
+52,230
| +48% | +$1.66M | 0.01% | 1735 |
|
|
2013
Q3 | $3.32M | Buy |
108,698
+28,445
| +35% | +$951K | 0.01% | 1936 |
|
|
2013
Q2 | $2.54M | Buy |
+80,253
| New | +$2.64M | ﹤0.01% | 2247 |
|
Citadel Advisors's GHDX Position: Q3 2019 in Review
Citadel Advisors sold out of Genomic Health, Inc. (GHDX) in Q3 2019, closing a stake of 291,969 shares — an estimated $20.1M sold.
Citadel Advisors first reported a position in GHDX in Q2 2013 and held it in 24 quarters. The position peaked at $24.9M in Q1 2019. 221 funds tracked by Wall St. Rank hold GHDX as of Q3 2019.
- Citadel Advisors reported no remaining Genomic Health, Inc. position as of Q3 2019 after selling out during the quarter.
- Citadel Advisors sold 291,969 Genomic Health, Inc. shares in Q3 2019, an estimated $20.1M.
- Citadel Advisors first reported a position in Genomic Health, Inc. in Q2 2013 and held it in 24 quarters.
- Citadel Advisors's Genomic Health, Inc. position peaked at $24.9M in Q1 2019.
- 221 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q3 2019.
Based on Citadel Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.